Approved February 2006
RotaTeq is a live, orally administered pentavalent vaccine containing 5 reassorted rotaviruses. The vaccine is designed to target the viral serotypes which are most common and most frequently associated with severe gastroenteritis.
RotaTeq is specifically indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the rotavirus serotypes G1, G2, G3, and G4 in infants between the ages of 6 to 32 weeks.
RotaTeq is supplied as a pale yellow clear suspension for oral delivery. A standard regimen is administered as three 2 ml oral doses: the first should be administered at 6-12 weeks of age, with subsequent doses administered on 4 to 10 week intervals (the last dose should be administered before the infant reaches 32 weeks of age).
Approval of RotaTeq was based on results of three phase III trials of the drug, which treated a combined 72.324 infants in 11 countries. Two of the studies, the Rotavirus Efficacy and Safety Trial (REST) and Study 007, were designed to investigate the efficacy of the drug; the third, Study 009, was designed to investigate the vaccine's safety and manufacturing consistency.
This placebo-controlled study investigated the primary efficacy of the vaccine (n=2834), compared to placebo (n=2839). In the primary efficacy analysis (including subjects finishing the vaccination course), all-severity gastroenteritis occurred in 82 subjects in the vaccine group, compared to 315 in the placebo group (74.0% efficacy); severe rotavirus gastroenteritis occurred in 1 vaccine subject, and 51 placebo subjects (98.0% efficacy). Intent to treat (ITT) analysis (including subjects receiving at least 1 dose of the vaccine) efficacy rates in all-severity and serious enteritis were 60.0% (n=150 vs. 371) and 96.4%, (n=2 vs. 55) respectively. Secondary efficacy measures were also positive, with the vaccine significantly reducing hospitalizations for gastroenteritis due to G1, G2, G3, and G4 rotavirus infection in both full-regimen (95.8% reduction; n=6 vs. 144) and ITT (94.7%; n=10 vs. 187) populations.
This placebo controlled study investigated the efficacy of the drug in reducing gastroenteritis due to rotavirus serotypes G1, G2, G3, or G4 during the fist viral season. Efficacy in reducing all-severity disease was 72.5% in the primary efficacy group, and 58.4% in the trial's ITT group. Efficacy in reducing incidence of severe disease for both primary and ITT populations was 100%.
Ongoing Study Commitments
Adverse events associated with the use of RotaTeq may include, but are not limited to, the following:
Intussusception, a serious gastrointestinal event which has been associated with previously approved rotavirus vaccines, occurred in 6 of 34,837 subjects receiving the vaccine at day 42, and 13 subjects by day 365, compared to 5 of 34,788 receiving placebo at day 42 and 15 subjects at day 365. The difference in incidence between these groups was not statistically significant, and none of the cases through 42 days in patients receiving the vaccine occurred following a single dose (the highest-intussusception risk period for earlier vaccines).
RotatTeq is designed to elicit immune response against a broad spectrum of Rotavirus strains. The vaccine is composed of 5 strains of live reassorted rotavirus. 4 of the strains express one of the capsid proteins (G1, G2, G3, G4) from the human rotavirus parent and the attachment protein P7 from bovine rotavirus. The fifth strain expresses the P1 attachment protein from the human rotavirus strain and the G6 bovine rotavirus capsid protein.
For additional information regarding RotaTeq or Rotavirus gastroenteritis, please visit the RotaTeq web page.
The Rotateq (rotavirus vaccine, live oral pentavalent) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.